Drug Profile
FAB 114
Alternative Names: FAB114Latest Information Update: 30 Aug 2023
Price :
$50
*
At a glance
- Originator Ferrer
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma
Most Recent Events
- 30 Aug 2023 Discontinued - Preclinical for Chronic lymphocytic leukaemia in Spain (unspecified route)
- 30 Aug 2023 Discontinued - Preclinical for Non-Hodgkin's lymphoma in Spain (unspecified route)
- 28 Feb 2020 No recent reports of development identified for preclinical development in Chronic-lymphocytic-leukaemia in Spain